<DOC>
	<DOC>NCT01754714</DOC>
	<brief_summary>Investigation the Effects of Different Doses of SAMe in Subjects with Nonalcoholic Fatty Liver Disease and non-treated matched healthy volunteers as control group</brief_summary>
	<brief_title>Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Inclusion Criteria Subjects with nonalcoholic steatohepatitis based on histology in medical history within the last 3 years Subjects in a stable metabolic condition since histology for NASH (Nonalcoholic Steatohepatitis) Exclusion Criteria Subjects with extrahepatic biliary obstruction Subjects with primary sclerosing cholangitis (PSC) Subjects with primary biliary cirrhosis (PBC) Any form of malignancy within the past 5 years and/or basal cell carcinoma and squamous cell carcinoma of the skin within the past two years History of active substance abuse (oral, inhaled or injected) within one year prior to the study Subjects with renal impairment (creatinine level of &gt;2.0 mg/dL) Subjects with a known hypersensitivity to the active substance (ademetionine) or methionine or to any of the inactive ingredients Subjects with known genetic defects affecting the methionine cycle and/or causing homocystinuria and/or hyperhomocysteinemia (e.g., cystathionine betasynthase deficiency, Vitamin B12 metabolism defect) Subjects on total parenteral nutrition in the year prior to screening Subjects after or planned for bariatric surgery (jejunoileal bypass or gastric weight loss surgery) Extrahepatic cholestasis (proven by ultrasound) Subjects with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt; 5 upper limit of normal (ULN) Subject with serum total bilirubin (STB) &gt; 5 ULN Subjects after liver transplantation and subjects on the waiting list for liver transplantation Subjects with any of the following disease in medical history: Viral hepatitis (serum positive HBcAb (hepatitis B core antibody) or Hepatitis C Virus (HCV) ribonucleic acid (RNA) Evidence of autoimmune liver disease Wilson's disease Hemochromatosis Alpha1antitrypsin deficiency Known positivity for antibody to human immunodeficiency virus (HIV) Known heart failure of New York heart Association class 3 or 4 Current or history of significant alcohol consumption for a period of more than three consecutive months within five years prior to screening (significant alcohol consumption is defined as &gt; 3 U (unit)/day for men and &gt; 2 U/day for women, on average) or binge drinking or inability to reliably quantify alcohol consumption. Clinical or histological evidence of cirrhosis F4 Subjects with history of biliary diversion Subjects with uncontrolled diabetes mellitus defined by HbA1c (hemoglobin A1c) &gt; 8.0 % at screening Concomitant medication of B12, folate, betaine or choline Concomitant treatment with glitazone within the past year prior to the study Subjects with known folate or B12 deficiency BMI (body mass index) &gt; 40 kg/m2 History of major depression diagnostic and statistical manual of mental disorders (DSMIV) or bipolar disease Women of childbearing potential: positive urine pregnancy test during screening or unwillingness to use an effective form of birth control during the study. Breastfeeding women Any condition that, in the opinion of the investigator, does not justify the patient's inclusion into the study Investigational drug intake within one month prior to the study Active, serious medical disease with likely lifeexpectancy less than five years Uncooperative attitude or reasonable likelihood for noncompliance with the protocol or any other reason that, in the investigator's opinion, prohibits the inclusion of the subject into the study Legal incapacity or limited legal capacity, or who are incarcerated. Inability to return for scheduled visits. Inability to understand and follow the requirements of the protocol in the local language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Steatohepatitis</keyword>
</DOC>